Trial | ||||
ECOG E2108[1] | Austria[2,3] | India[4] | Turkey MF07-01[5] | |
Accrual period | 2011 to 2015 | 2011 to 2015 | 2005 to 2013 | 2007 to 2012 |
Number of patients | 256 | 90 | 350 | 274 |
Inclusion | De novo stage IV breast cancer on systemic therapy for 4 to 8 months without progression | Stage IV breast cancer | De novo stage IV breast cancer with resectable hormone receptor-positive disease, or others with a partial or complete response to anthracycline-based chemotherapy | De novo stage IV breast cancer |
Prerandomization systemic therapy | Optimal systemic therapy × 4 to 8 months | None | 6 to 8 cycles of anthracycline-based chemotherapy | None |
Stratification |
|
|
| None |
Locoregional therapy in surgery group |
|
|
|
|
Median follow-up (months) | 53 | 37.5 | 23 | 40 |
OS (surgery versus no surgery) |
|
|
|
|
LRP (surgery versus no surgery) | LRP 10 versus 26%, p = 0.003 | LRP 9 versus 18%, p = 0.22 | LRP-free survival: Median not attained versus 18.2 months; HR 0.16, 95% CI 0.10-0.26; p <0.0001 | LRP 1 versus 11%, p = 0.001 |
Quality of life | Worse in surgery group at 18 months; no difference at 6 or 30 months | No difference | Not reported | Not reported |
Do you want to add Medilib to your home screen?